Fig. 2

Comparative oncology assessment of KPT-335 in tumor-bearing dogs. Two distinct Phase 1 studies were performed to explore tolerability and efficacy in dogs with a variety of cancer types. In Phase 2, a focused study in dogs with lymphoma (LSA) was conducted to explore several dosing methods and schedules with PK data gathered form a subset of patients. MCT: mast cell tumor, OSA: osteosarcoma, PE: physical exam, QOL: quality of life assessment survey, CBC: complete blood count, chem: serum chemistry panel, UA: urinalysis, Q2W: every 2 weeks, PD: progressive disease, PK: pharmacokinetics